

BMJ Open Training inhibitory control in adolescents with elevated attention deficit hyperactivity disorder traits: a randomised controlled trial of the Alfi Virtual Reality programme

Erin McKay , Hannah Kirk, James Coxon, Danielle Courtney, Mark Bellgrove, Aurina Arnatkeviciute, Kim Cornish

To cite: McKay E, Kirk H, Coxon J, *et al.* Training inhibitory control in adolescents with elevated attention deficit hyperactivity disorder traits: a randomised controlled trial of the Alfi Virtual Reality programme. *BMJ Open* 2022;**12**:e061626. doi:10.1136/bmjopen-2022-061626

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-061626>).

EM and HK are joint first authors.

Received 07 February 2022
Accepted 18 July 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia

Correspondence to

Erin McKay;
Erin.McKay@monash.edu

ABSTRACT

Introduction Attention deficit hyperactivity disorder (ADHD) is characterised by significant deficits in attention and inhibition. These deficits are associated with negative sequelae that emerge in childhood and often continue throughout adolescence. Despite these difficulties adolescents with ADHD often demonstrate poor treatment compliance with traditional interventions (eg, psychostimulant medication). Virtual reality (VR) presents an innovative means of delivering engaging cognitive interventions for adolescents with ADHD and offers the potential to improve compliance with such interventions. The current parallel, randomised controlled trial aims to evaluate the effects of a VR intervention (Alfi) designed to improve inhibition in adolescents with ADHD.

Methods and analysis A sample of 100 adolescents (aged 13–17) with elevated ADHD symptoms will be recruited from secondary schools and ADHD organisations located in the state of Victoria, Australia. Participants will be randomly assigned to either an 8-week VR intervention or a usual care control. The VR intervention involves the completion of 14 sessions, each 20 min in duration. Participants will complete computerised assessments of inhibition and risk-taking preintervention and immediately postintervention. Parents/guardians will complete online questionnaires about their child's ADHD symptoms and social functioning at each of these timepoints. The primary outcome is change in inhibition performance in adolescents who received the intervention from preintervention to postintervention compared with adolescents in the control condition. Secondary outcomes include change in risk-taking, ADHD symptoms and social functioning in adolescents who received the intervention from preintervention to postintervention compared with adolescents in the control condition. If the intervention is shown to be effective, it may offer a supplementary approach to traditional interventions for adolescents with ADHD experiencing inhibitory control difficulties.

Ethics and dissemination This trial has ethics approval from the Monash University Human Research Ethics Committee (HREC) (21530) and the Victorian Department of Education and Training HREC (2020_004271). Results will be disseminated through peer-reviewed journals,

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ The intervention used in the study is a novel virtual reality programme designed to train inhibitory control in adolescents with elevated attention deficit hyperactivity disorder symptoms.
- ⇒ The trial follows an established framework (the Obesity-Related Behavioral Intervention Trials [ORBIT] model) for designing and evaluating interventions.
- ⇒ The study includes measures to assess the near and far transfer of trained skills.
- ⇒ The inclusion of participants with autism spectrum disorder and other common comorbidities contributes to the ecological validity of the findings.
- ⇒ A limitation of the study is the use of a usual care active control group rather than a placebo virtual reality task due to ethical concerns.

conference proceedings and community activities. Individual summaries of the results will be provided to participants on request.

Trial registration number ACTRN12620000647932.

INTRODUCTION

Attention deficit hyperactivity disorder (ADHD) is a common childhood disorder with a prevalence of approximately 7% among school-aged children.¹ ADHD is characterised by significant cognitive and behavioural deficits, with diagnosis based on age-inappropriate and impairing levels of inattention and/or hyperactivity and impulsivity.² These symptoms have a significant impact on daily functioning and are associated with a range of negative sequelae, including poor academic achievement, social difficulties, mental health problems and overall poorer quality of life.³

Not only are the difficulties associated with ADHD far-reaching, they are also enduring.

Symptoms and functional impairment emerge during childhood and often persist throughout adolescence and beyond, with an estimated prevalence of 3% for adults with ADHD.⁴ Despite the significant, long-lasting consequences of ADHD symptoms, treatment compliance remains a challenge in adolescents with ADHD. While pharmacological treatments have efficacy in managing ADHD symptoms,⁵ it is estimated that around half of adolescents with ADHD exhibit some non-compliance.⁶ High levels of non-compliance coupled with the social and academic consequences of unmanaged ADHD symptoms necessitate the development of appealing and engaging treatment options that can complement and supplement pharmacological treatment.

Cognitive training has been suggested as an engaging and potentially effective intervention for many clinical populations, including children with ADHD, and may offer an adjunctive intervention to medication.^{7,8} Cognitive training is based on the premise of neural plasticity and asserts that deficits in cognitive functions can be improved long term through repeated, targeted training.⁹ Many cognitive training interventions have targeted cognitive difficulties in ADHD with mixed results.^{9,10} These interventions have predominantly focused on improving cognitive skills such as working memory.⁸ However, a large body of research indicates that inhibition is a central cognitive deficit in ADHD.^{11,12} Inhibition can be defined as the voluntary control of responses and stimuli, and deficits in inhibition can contribute to behavioural and social problems in adolescents with ADHD.¹³ Previous investigations of computerised inhibitory control training in children with ADHD have shown positive impacts of the intervention on symptoms of ADHD.¹⁴ However, to date no study has investigated the potential benefits of inhibition training in adolescents with ADHD.

Computer-based and digital training tools offer an innovative platform to deliver these cognitive interventions, with one particularly engaging and emerging tool being virtual reality (VR). VR provides an immersive environment that helps to limit extraneous distractions, making it a promising tool to target cognitive functioning.¹⁵ For children and adolescents with ADHD, VR is particularly beneficial due to its novel and dynamic format which allows for better focus and concentration on a task by excluding distractions in the real world.

There has been increasing interest in the use of VR as a means of delivering assessments and interventions in ADHD. While there are no known trials of VR-based interventions for adolescents with ADHD, the results of VR-based assessment studies have been promising.^{16–18} VR-delivered assessment tasks such as the continuous performance task (CPT), a common measure of assessing sustained attention, demonstrate greater ability to differentiate between children with and without ADHD and increased ecological validity when compared with traditional versions of the task.^{16–19} While traditional CPT tasks in children with and without ADHD tend to show difference in reaction time of medium effect size, in VR these

differences were of large effect size.¹⁷ This increased sensitivity and ecological validity has been one of the key drivers for the use of VR in children with ADHD. Furthermore, these studies provide evidence of the usability and tolerability of VR in adolescents with ADHD.

Objectives

Although cognitive training interventions delivered via VR show considerable promise as a means of remediating cognitive deficits in adolescents with ADHD,²⁰ the novel nature of VR and the lack of VR-based interventions for ADHD mean that it is yet to be widely tested. The Alfi Virtual Reality (Alfi VR) programme aims to fill this gap. Alfi VR was designed to train inhibitory control in adolescents with ADHD. While an initial proof-of-concept trial has been completed in typically developing adolescents, Alfi VR is yet to be trialled in adolescents with significant inhibitory control deficits, such as those with ADHD. The primary objective of this pilot study is therefore to assess whether completion of the Alfi VR programme is associated with any change in inhibitory control in adolescents with ADHD as compared with usual care.

It is hypothesised that Alfi VR will be associated with significant improvements in the primary outcome measure of response inhibition when compared with usual care. The secondary objective of the trial is to assess for any improvements in related, untrained domains such as impulsivity, ADHD symptoms, emotion regulation and social skills following completion of the Alfi VR intervention as this will help determine whether training leads to changes in functional outcomes. An additional exploratory analysis will be conducted to assess the impact of sociodemographic (eg, family environment and socioeconomic status) and prognostic (eg, social anxiety) factors on change in the primary outcome from preintervention to postintervention.

METHODS AND ANALYSIS

Study design and setting

The Alfi VR trial is an unblinded, randomised controlled trial with two parallel groups and equal allocation ratio (1:1). The effects of the VR intervention compared with a usual care control will be assessed preintervention (week 1) and immediately postintervention (week 9). The trial will be conducted and reported in accordance with the Consolidated Standards of Reporting Trials statement.

The trial will be run across two urban, Australian community-based settings. Data collection and intervention sessions will be run at participating government and independent schools across metropolitan Melbourne and at Monash University. The trial commenced in February 2020, with an estimated completion date of August 2022.

Patient and public involvement

The public were able to provide feedback on the intervention during a proof-of-concept trial of Alfi VR. Proof-of-concept phases represent a key step in ensuring the

appropriateness of the intervention prior to undertaking a pilot study. Typically developing teenagers from Melbourne, Australia were invited to participate in three Alfi training sessions, after which they provided feedback on the enjoyability, usability and accessibility of the training programme. This feedback was incorporated into the latest build of Alfi VR, which is being used for this trial, and was informed the timing and number of sessions in the current trial. Details of dissemination of results to participants and the public can be found under the Ethics and dissemination section.

Eligibility criteria

The study is targeted at adolescents, which is defined by the WHO as children between 13 and 19 years of age.²¹ Children will be eligible to participate in the trial if they are (1) aged between 13 years and 17 years 11 months at the time of enrolment into the study and (2) have elevated ADHD symptoms. Elevated symptoms are defined as t-scores above 58 on either the inattention or hyperactive/impulsive scales, or a t-score of above 58 on either the ADHD inattentive or ADHD hyperactive/impulsive Diagnostic and Statistical Manual of Mental Disorders: Text Revision (DSMIV-TR) scales of the Conners-3 Parent Rating Scale. Children will be excluded if they have (1) a diagnosis of developmental delay or borderline intellectual delay (defined as a Full Scale IQ of less than 80 on the Kaufman Brief Intelligence Test - Second Edition (KBIT-2)); (2) a history of neurological impairment including epilepsy, acquired brain injury or any history of seizures; and (3) any sensory or motor impairment or comorbid diagnosis that may prevent them from completing the intervention or understanding study instructions (eg, visual impairment, paralysis, severe obsessive-compulsive disorder). Screening questions pertaining to all exclusion criteria will be included in the demographic questionnaire, and clarification from parents/caregivers will be sought where responses are ambiguous or the level of impairment is unclear. Details of current medication use will be obtained through the demographic questionnaire. Children who are on a stable dosage will not be excluded from enrolling in the study; however, changes to dose or commencement of medication will result in withdrawal from the trial (see the Discontinuation criteria section).

Intervention

The intervention is an inhibitory control training intervention called Alfi VR. The Alfi VR intervention uses immersive VR technology to deliver a game-based version of an anticipated response stop-signal task.²² This paradigm has been used in studies of children with ADHD previously, with children with ADHD showing deficits on this task when compared with typically developing (TD) controls.²³ Anticipated response versions of the stop-signal task require a fixed go response initiation time, rather than a speeded response as in reaction time versions of the stop-signal task. This affords greater control over the timing of the go response, and by extension the timing

of stop cues relative to the go response.²⁴ Furthermore this paradigm has been well characterised as targeting behavioural response inhibition.²⁴ The intervention is graded in difficulty and includes task conditions that train reactive and proactive inhibition,^{25–30} as well as selective inhibition.^{31–35} As such, the Alfi VR intervention is immersive and challenging and targets core cognitive processes involved in inhibitory control throughout the course of training.

Adolescents are equipped with an HTC Vive VR headset and two controllers, with base stations mounted on stands. Within the programme users play the role of a wizard who must protect a magic crystal from dragon attacks by casting spells. Users are required to hold down the triggers on both controllers at the start of each trial. In Go trials, users release the triggers to cast spells at certain times to defuse the dragon's fireball attacks (figure 1A). At the start of the intervention, the dragon's fireball attacks occur on both sides, requiring users to release both triggers on the controllers. As the intervention progresses, the Stop trials are introduced requiring the user to inhibit their primed response to simultaneously release both fireballs on a proportion of trials (25%). In the first block that includes the Stop trials, wizards are introduced who are also able to cast spells and defuse the fireballs. When a wizard has defused a fireball, users must inhibit any initiated responses (eg, trigger releases), otherwise the fireball will become active once more (figure 1B). The timing of the wizard spell represents the stop signal delay (SSD). The SSD represents the amount of time between the onset of the Go signal and the Stop signal, with a longer SSD often associated with increased errors.³⁶ The tracking method is used to adjust the SSD, increasing and decreasing by 33ms (approximately two screen refreshes) depending on the correct or incorrect responding on the previous Stop trial.²⁴

As the levels increase in difficulty, the fireballs may also occur from either the right or left side only, requiring one trigger to be held down while the other is released (selective inhibition; figure 1C), and cues are introduced which indicate the increased likelihood of the next trial being a stop trial (proactive inhibition; figure 1D). The use of a bimanual and selective paradigm requires the participant to attend to multiple streams of information simultaneously, increasing the ecological validity of the training. Furthermore, the introduction of cues in later trials (indicating the increased likelihood of a stop trial) allows for proactive inhibition to be trained in addition to reactive inhibition.

By providing variability in trial types and having an adaptive SSD, the potential for maintaining participant engagement is maximised. These variables ensure that the task remains challenging without becoming too difficult. Participants receive feedback on all responses, which includes corrective feedback when participants respond incorrectly or fail to respond. To provide motivation throughout training sessions, participants can monitor their progress and in-game statistics and receive virtual




Figure 1 Trial structure and timing. 1a. Go trials; 1b. Bimanual stop trials; 1c. Selective stop trials; 1d. Stop trials with cues (bimanual shown). L = Left; R = Right.

ingame rewards that can be used to personalise certain aspects of gameplay.

Researchers will observe and monitor participant progress throughout the session via the computer monitor. Training sessions take 20 min to complete, with each block within the session lasting approximately 6 min. The individual blocks comprise a 3:1 ratio of Go trials (75%) to Stop trials (25%). Participants will complete the Alfi programme twice per week for 8 weeks, totalling 16 training sessions. The dates and times of all training sessions are recorded to monitor treatment adherence, with treatment compliance defined as having completed 12 of the 16 allocated training sessions (75%).

Discontinuation criteria

Participants may be withdrawn from the trial if they (1) commence any medication or therapy for the purpose of addressing ADHD symptoms or if there are any changes to their current treatment (eg, increase in medication dosage); (2) experience recurrent or persistent symptoms of cybersickness; or (3) experience a serious adverse event.

Outcomes

Primary outcome

All outcome measures were designed to be used with adolescents and are appropriate for use in children with ADHD. The first primary outcome of the study will be the difference in pretraining to post-training response inhibition between the Alfi VR intervention group and the control group. Response inhibition will be measured using an anticipated response stop-signal task designed

to assess the ability to inhibit prepotent responses. This task has been designed in line with recommendations in the 2019 consensus statement on stop-signal tasks³⁷ and is similar in structure to the Alfi VR intervention and our previous work.^{22 24 26} The anticipated response task is completed on a laptop computer. The task comprises a short practice block of 5 Go trials, followed by a block of 30 Go trials. Participants are then presented with another practice block of 10 trials, of which 5 are Stop trials. These practice trials are followed by 5 blocks of 40 trials, each comprising 25% Stop trials. The tracking method is used to adjust the SSD with a step size of 25 ms, initialised at 500 ms, and bounds of 50 ms and 775 ms.

During the task participants are required to focus on the yellow target markers. In Go trials, participants must then hold down the space bar and release the space bar once the indicator bar the yellow target. In Stop trials, the indicator bar stops prematurely, requiring participants to inhibit the primed response to release the response key. Reactive response inhibition will be assessed by determining the stop-signal response time (SSRT) using the integration method, with reductions in SSRT indicative of improvements in inhibitory control. Proactive response inhibition will be calculated by comparing the Go reaction time between the block containing only Go trials and the blocks comprising both Stop and Go trials.

Secondary outcomes

The secondary outcome measures are outlined in table 1. These measures cover a range of domains commonly impaired in ADHD, including behavioural attention,

Table 1 Schedule of measures

Outcome	Measure	Administration		Timepoint	
		Participant	Parent	Screening	Post-training
Screening					
ADHD symptoms	Conners-3		x	x	
FSIQ	Kaufman Brief Intelligence Test - Second Edition	x		x	
Demographics	Demographic questionnaire		x	x	
Primary outcome					
Response inhibition	Anticipated response task	x			x
Secondary outcomes					
Cognitive attention	Attention network task	x			x
Behavioural attention	Strengths and Weaknesses of ADHD and Normal Behaviour		x		x
Risk-taking	Balloon Analogue Risk Task - Youth	x			x
Verbal working memory	Digit span	x			x
Impulsivity	UPPS-P	x			x
Executive function	BRIEF-2	x	x		x
Emotion regulation	Perth Emotion Regulation Competency Inventory	x			x
Social skills	Social Skills Questionnaires	x			x
Quality of life	Assessment of Quality of Life	x			x
Additional measures					
Autism features	Social Responsiveness Scale - Second Edition		x	x	
Family functioning	Family Assessment Device		x		x
Anxiety	Spence Children's Anxiety Scale	x			x
Behavioural and emotional problems	Child Behavior Checklist		x		x
Emotion recognition	NEPSY-II	x			x
Theory of mind	NEPSY-II	x			x

ADHD, attention deficit hyperactivity disorder; BRIEF-2, Behavior Rating Inventory Executive Function, 2nd edition; FSIQ, Full Scale Intelligence Quotient; NEPSY-II, NEPSY 2nd Edition; SWAN, Strengths and Weaknesses of ADHD and Normal Behavior; UPPS-P, Urgency, Premeditation, Perseverance, Sensation Seeking, and Positive Urgency.

impulsivity, risk-taking behaviour, autism features and social skill. These measures have been included to assess whether far transfer occurs following completion of the intervention.

Additional measures

Additional measures have been included based on previous research which highlights the impact of factors such as anxiety and socioeconomic status on cognitive development and training outcomes.^{38–39} Measures of autism symptoms and emotional and behavioural concerns have also been included due to the high comorbidity between ADHD and other disorders that may be associated with differences and changes in inhibitory control, such as autism spectrum disorder (ASD), oppositional defiant disorder and mood disorders.^{40–42} The psychometric properties of all measures are outlined in table 2.

Sample size calculation

A priori power analysis was conducted in G*Power V.3.1 to determine the necessary sample size required to detect significant changes in inhibitory control from pretraining (baseline) to post-training between groups. An estimated effect size of 0.3 was used based on the results of a small proof-of-concept study of the Alfi intervention in typically developing adolescents conducted by the authors. A total sample size of 97 was required for a power of 90%. The study will therefore aim to recruit 100 participants, with 50 per group assuming a 1:1 allocation ratio. This is consistent with previous trials evaluating cognitive training interventions in individuals with ADHD.⁴³

Recruitment

Participants will be recruited through a number of avenues. The primary recruitment pathway will be through local government and independent schools. Researchers will contact schools within 40km of the Monash University Clayton campus. A sampling matrix will be used to ensure that participants are recruited from a range of geographical regions across metropolitan Melbourne and to ensure diversity within the sample with regard to socioeconomic status. Interested schools will be provided with study information packs to disseminate to students and their families.

Participants will additionally be recruited via ADHD-related websites, community groups and ADHD-related social media groups. Due to the requirement for intervention sessions to take place at schools or at Monash University, it is anticipated that participants will predominantly reside in metropolitan Melbourne.

Interested families will contact the research team directly via phone or email and will be given the opportunity to discuss the study further. If families complete the informed consent form, they will be invited to participate in screening. Screening will take place online, with parents emailed a link to the demographic questionnaire and the Conners-3 Parent Rating Scale, which will be used

to confirm clinical diagnosis of ADHD. Should children meet all the inclusion criteria and none of the exclusion criteria, they will be accepted into the trial.

Participant timeline/procedure

The timing of screening, randomisation, assessments and intervention can be seen in figure 2. The pretraining intervention will take place a week prior to the commencement of the intervention. The intervention period will run for 8 weeks, with the post-training assessment taking place a week after completion of the intervention. Refer to figure 2 for the intervention and assessment schedule.

Allocation

Participants will be randomised following completion of the pretesting assessment. Block randomisation will be used, with blocks of four. As there are significant sex differences within ADHD,^{44–45} randomisation will be stratified by sex to ensure an even distribution of boys and girls between the intervention and control groups. Randomisation will be completed by a member of the research team using R. Group allocation will be communicated to participants and their families and recorded in the study database.

Concealment

Group allocation will be completed by an independent researcher who is not a member of the trial study team to reduce bias. A randomisation sequence will be generated in RStudio and printed onto folded cards with the group allocation listed on the inside. Following enrolment into the study, the participants' study identification will be provided to the independent researcher, who will record it on the outside of the card and provide it to the trial researcher in a sealed opaque envelope. Following completion of the pretraining assessment, the envelope will be opened and the participant assigned to their allocated group.

Statistical methods

Data obtained during screening will be analysed to determine study eligibility; no further interim analysis will be conducted. At the completion of the trial, study data will be analysed using an intention-to-treat approach, meaning that outcome data for all participants will be included regardless of treatment compliance. Primary outcome data will be analysed in SPSS version 27 using analysis of covariance (ANCOVA) to examine changes in response inhibition from pretraining to post-training between groups. ANCOVA will allow for inclusion of covariates to minimise the impact of extraneous variables such as age, ASD traits (as measured by the Social Responsiveness Scale, 2nd Edition (SRS-2)) or cognitive function (as measured by the KBIT-2), where indicated. Multivariate analysis of covariance will be used to analyse differences in secondary outcome measures, with post-hoc tests completed for any significant results.

After completion of the primary intention-to-treat analysis, a sensitivity analysis using a per-protocol approach

Table 2 Psychometric properties of measures

Measure	Domain	Psychometric properties
Conners-3 Parent Rating Scale*†	ADHD symptoms	Internal consistency 0.90–0.91, test–retest reliability coefficient 0.85–0.89, inter-rater reliability 0.81–0.84, good convergent validity with the BASC and BRIEF, good discriminant validity. ⁴⁸
KBIT-2*†	General cognition	Good internal consistency across composites for adolescents (0.87–0.94) and convergent validity. ⁴⁹
Anticipated response task	Response inhibition	When compared with choice response and simple response time versions, anticipated response provided more reliable estimate. ²⁴
BART-Y	Risk-taking	Good stability of measurement and incremental validity. ⁵⁰
ANT	Cognitive attention	Review of reliability indicates satisfactory reliability, with the executive control measure demonstrating the highest reliability. Good validity based on neuroimaging data and behavioural studies. ⁵¹
Digit span*	Verbal working memory	Modified administration and scoring of backward digit span in children with ADHD has been shown to increase validity of this measure. ⁵²
NEPSY-II† Affect recognition and theory of mind	Social cognition	Strong internal reliability. Small intercorrelation between affect recognition and theory of mind subtests (0.21), indicating these subtests are measuring distinct social cognition abilities, indicative of good validity. ⁵³
BRIEF-2*†	Executive function	Internal consistency coefficient of 0.76–0.97 on parent report and 0.71–0.97 on self-report. Test–retest correlations of 0.67–0.92. Moderate to strong concurrent validity. ⁵⁴ Good validity in ADHD samples. ⁵⁵
SWAN*	ADHD symptoms	High convergent validity. ⁵⁶ Review of seven studies indicated good reliability. ⁵⁷
UPPS-P*	Impulsivity	Good internal consistency. Ranges from 0.82 to 0.91 for four original subscales. Good content validity. ⁵⁸ Short version demonstrated good discriminant validity for ADHD in children. ⁵⁹
AQoL	Quality of life	Demonstrated validity with other multiattribute utility instruments and greater sensitivity than comparison measures. ⁶⁰
PERCI	Emotion regulation	Good reliability, $\alpha=0.84$ – 0.95 across subscales and composites. ⁶¹
SSQ	Social skills	Good split-half reliability (0.83) and coefficient alpha of 0.85. Good validity demonstrated by significant correlation with parent ratings ($r=0.43$). ⁶²
SCAS†	Anxiety	High internal consistency ($\alpha=0.87$ – 0.94) and test–retest reliability (0.63). Good construct and convergent validity. ^{63 64}
CBCL*†	Behavioural and emotional problems	Good concurrent validity. Valid tool for screening for comorbidities in children and adolescents with ADHD. ^{65 66}
SRS-2†	Autism symptoms	Strong internal consistency (0.94–0.96). Good predictive validity with sensitivity and specificity values of 0.92. Good concurrent validity with moderate to strong correlations with other comparable measures. ⁶⁷
FAD†	Family functioning	Good reliability (>0.70) and sensitivity. ^{68 69}

*Measure has been validated with a paediatric ADHD sample.

†Measure has been validated in clinical samples.

ADHD, attention deficit hyperactivity disorder; ANT, Attention Network Task; AQoL, Assessment of Quality of Life; BART-Y, Balloon Analogue Risk Task, Youth; BRIEF-2, Behavior Rating Inventory of Executive Function; CBCL, Child Behavior Checklist; FAD, Family Assessment Device; KBIT-2, Kaufman Brief Intelligence Test - Second Edition; NEPSY-II, NEPSY 2nd Edition; PERCI, Perth Emotion Regulation Competency Inventory; SCAS, Spence Child Anxiety Scale; SRS-2, Social Responsiveness Scale, 2nd Edition; SSQ, Social Skills Questionnaire; SWAN, Strengths and Weaknesses of ADHD and Normal Behavior; UPPS-P, Urgency, Premeditation, Perseverance, Sensation Seeking and Positive Urgency.

will be conducted to assess the robustness of the results and to determine whether there are any differences in outcomes between participants who met the criteria for programme compliance and those who did not.⁴⁶ The management of missing data will be dependent on the amount of data missing and the pattern of missing data.⁴⁷

Data collection/data management

Data will be collected by researchers trained in the administration and scoring of the study assessment measures. In week 1 families will be emailed links to the pretraining surveys for completion by the participant and a parent. These surveys take approximately 25 min to complete and responses can be saved and the survey resumed at a later




Figure 2 Intervention and assessment schedule.

time if required. Participants will concurrently complete the pretraining assessment session at week 1. This session will take place face-to-face and will be facilitated by two researchers. Following the 8-week intervention period, families will be emailed links to the post-training surveys and participants will concurrently complete the face-to-face post-training assessment session. These surveys must be completed within 2 weeks of completing the intervention. Study progress will be recorded for each participant in the study database.

Participant data will comprise a combination of electronic and paper-based records. Electronic data will be recorded and stored within a secure Research Electronic Data Capture (REDCap) database. Paper-based data will be identified by participant number only and will be stored securely and retained in accordance with relevant government regulations. As the study is unblinded a data monitoring committee was not deemed necessary. This role will be undertaken by the study team.

ETHICS AND DISSEMINATION

The Alfi VR trial has ethics approval from the Monash University Human Research Ethics Committee (HREC) (project ID: 21530) and the Victorian Department of Education and Training HREC. The Alfi VR trial comprises adolescents aged 13–17 years and therefore written informed consent will be obtained from the parent or primary caregiver in addition to assent from adolescents.

As the Alfi VR intervention will be completed during scheduled class time, ethical concerns regarding removing children from the classroom to complete an inactive VR

task with no perceivable benefits prevent the use of an active control programme. The use of a usual care active control group mitigates this concern by not disadvantaging children through missed educational activities.

At the conclusion of the study parents will be provided with a summary of their child's individual performance on request. Researchers will offer to run information sessions at each participating school to share deidentified study findings with participants and their families. A community-based seminar will also be organised to disseminate study findings, and findings will be shared on the study website for public access. The findings of the trial will be published in journals and conference proceedings and will form part of a PhD thesis. All published and disseminated data will be deidentified and analysed as a group to ensure confidentiality and protect the privacy of participants.

The protocol and study information can be publicly accessed through the Australian New Zealand Clinical Trials Registry. Enrolled participants will be notified of any relevant changes to the protocol.

Acknowledgements The authors would like to thank Ms Rachael Martin for her assistance with manuscript preparation.

Contributors HK and KC were responsible for the initial conception of the work. EM and DC contributed to study design, with input from MAB and JC. EM wrote the initial manuscript draft, with subsequent drafts written by EM and with input from HK, DC, JC, AA, MAB, HK and KC reviewed and provided feedback on all drafts. Revision was completed by EM and HK. The revised and final manuscript was approved by all authors.

Funding This work was supported by a philanthropic donation from the 5Point Foundation and Australian Government Research Training Program (RTP) scholarships awarded to EM.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods and analysis section for further details.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Erin McKay <http://orcid.org/0000-0001-8347-5236>

REFERENCES

- Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. *Neurotherapeutics* 2012;9:490–9.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington VA; 2013.
- Tseng W-L, Gau SS-F. Executive function as a mediator in the link between attention-deficit/hyperactivity disorder and social problems. *J Child Psychol Psychiatry* 2013;54:996–1004.
- Simon V, Czobor P, Bálint S, *et al*. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *Br J Psychiatry* 2009;194:204–11.
- Cortese S, Adamo N, Del Giovane C, *et al*. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder

- in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2018;5:727–38.
- 6 Barnard-Brak L, Roberts B, Valenzuela E. Examining breaks and resistance in medication adherence among adolescents with ADHD as associated with school outcomes. *J Atten Disord* 2020;24:1148.
 - 7 Tamm L, Epstein JN, Peugh JL, et al. Preliminary data suggesting the efficacy of attention training for school-aged children with ADHD. *Dev Cogn Neurosci* 2013;4:16.
 - 8 Veloso A, Vicente SG, Filipe MG. Effectiveness of cognitive training for school-aged children and adolescents with attention deficit/hyperactivity disorder: a systematic review. *Front Psychol* 2019;10:2983.
 - 9 Sta Maria NS, Sargolzaei S, Prins ML, et al. Bridging the gap: mechanisms of plasticity and repair after pediatric TBI. *Exp Neurol* 2019;318:78–91.
 - 10 Sonuga-Barke E, Brandeis D, Holtmann M, et al. Computer-based cognitive training for ADHD: a review of current evidence. *Child Adolesc Psychiatr Clin N Am* 2014;23:807–24.
 - 11 Chambers CD, Garavan H, Bellgrove MA. Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. *Neurosci Biobehav Rev* 2009;33:631–46.
 - 12 McAuley T, Crosbie J, Charach A, et al. The persistence of cognitive deficits in remitted and unremitted ADHD: a case for the state-independence of response inhibition. *J Child Psychol Psychiatry* 2014;55:292–300.
 - 13 Bunford N, Brandt NE, Golden C, et al. Attention-deficit/hyperactivity disorder symptoms mediate the association between deficits in executive functioning and social impairment in children. *J Abnorm Child Psychol* 2015;43:133–47.
 - 14 Meyer KN, Santillana R, Miller B, et al. Computer-based inhibitory control training in children with attention-deficit/hyperactivity disorder (ADHD): evidence for behavioral and neural impact. *PLoS One* 2020;15:e0241352.
 - 15 Shema-Shiratzky S, Brozgol M, Cornejo-Thumm P, et al. Virtual reality training to enhance behavior and cognitive function among children with attention-deficit/hyperactivity disorder: brief report. *Dev Neurorehabil* 2019;22:431–6.
 - 16 Adams R, Finn P, Moes E, et al. Distractibility in Attention/Deficit/hyperactivity disorder (ADHD): the virtual reality classroom. *Child Neuropsychol* 2009;15:120–35.
 - 17 Neguț A, Jurma AM, David D. Virtual-reality-based attention assessment of ADHD: ClinicaVR: Classroom-CPT versus a traditional continuous performance test. *Child Neuropsychol* 2017;23:692–712.
 - 18 Parsons TD, Bowerly T, Buckwalter JG, et al. A controlled clinical comparison of attention performance in children with ADHD in a virtual reality classroom compared to standard neuropsychological methods. *Child Neuropsychol* 2007;13:363–81.
 - 19 Rodríguez C, Areces D, García T, et al. Comparison between two continuous performance tests for identifying ADHD: traditional vs. virtual reality. *Int J Clin Health Psychol* 2018;18:254–63.
 - 20 Bashiri A, Ghazisaeedi M, Shahmoradi L. The opportunities of virtual reality in the rehabilitation of children with attention deficit hyperactivity disorder: a literature review. *Korean J Pediatr* 2017;60:337.
 - 21 World Health Organisation. Adolescent health. Available: <https://www.who.int/health-topics/adolescent-health>
 - 22 Coxon JP, Stinear CM, Byblow WD. Intracortical inhibition during volitional inhibition of prepared action. *J Neurophysiol* 2006;95:3371–83.
 - 23 Gilbert DL, Huddleston DA, Wu SW, et al. Motor cortex inhibition and modulation in children with ADHD. *Neurology* 2019;93:e599–610.
 - 24 Leunissen I, Zandbelt BB, Potocanac Z, et al. Reliable estimation of inhibitory efficiency: to anticipate, choose or simply react? *Eur J Neurosci* 2017;45:1512.
 - 25 Aron AR. From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. *Biol Psychiatry* 2011;69:E55–68.
 - 26 Leunissen I, Coxon JP, Swinnen SP. A proactive task set influences how response inhibition is implemented in the basal ganglia. *Hum Brain Mapp* 2016;37:4706–17.
 - 27 Smittenaar P, Rutledge RB, Zeidman P, et al. Proactive and reactive response inhibition across the lifespan. *PLoS One* 2015;10:e0140383.
 - 28 Vink M, Zandbelt BB, Gladwin T, et al. Frontostriatal activity and connectivity increase during proactive inhibition across adolescence and early adulthood. *Hum Brain Mapp* 2014;35:4415–27.
 - 29 Zandbelt BB, Bloemendaal M, Neggers SFW, et al. Expectations and violations: delineating the neural network of proactive inhibitory control. *Hum Brain Mapp* 2013;34:2015–24.
 - 30 Zandbelt BB, Vink M. On the role of the striatum in response inhibition. *PLoS One* 2010;5:e13848.
 - 31 Bedard A-C, Nichols S, Barbosa JA, et al. The development of selective inhibitory control across the life span. *Dev Neuropsychol* 2002;21:93–111.
 - 32 Coxon JP, Stinear CM, Byblow WD. Selective inhibition of movement. *J Neurophysiol* 2007;97:2480–9.
 - 33 Aron AR, Verbruggen F. Stop the presses: dissociating a selective from a global mechanism for stopping. *Psychol Sci* 2008;19:1146–53.
 - 34 Coxon JP, Stinear CM, Byblow WD. Stop and go: the neural basis of selective movement prevention. *J Cogn Neurosci* 2009;21:1193–203.
 - 35 Coxon JP, Goble DJ, Leunissen I, et al. Functional brain activation associated with inhibitory control deficits in older adults. *Cereb Cortex* 2016;26:12–22.
 - 36 Verbruggen F, Logan GD. Response inhibition in the stop-signal paradigm. *Trends Cogn Sci* 2008;12:418–24.
 - 37 Verbruggen F, Aron AR, Band GP, et al. A consensus guide to capturing the ability to inhibit actions and impulsive behaviors in the stop-signal task. *Elife* 2019;8. doi:10.7554/eLife.46323. [Epub ahead of print: 29 04 2019].
 - 38 Eysenck MW, Derakshan N, Santos R, et al. Anxiety and cognitive performance: attentional control theory. *Emotion* 2007;7:336–53.
 - 39 Letourneau NL, Duffett-Leger L, Levac L. Socioeconomic status and child development: a meta-analysis. *J Emot Behav Disord* 2013;21:211–24.
 - 40 Barnett R, Maruff P, Vance A. Neurocognitive function in attention-deficit-hyperactivity disorder with and without comorbid disruptive behaviour disorders. *Aust N Z J Psychiatry* 2009;43:722–30.
 - 41 Schmitt LM, White SP, Cook EH, et al. Cognitive mechanisms of inhibitory control deficits in autism spectrum disorder. *J Child Psychol Psychiatry* 2018;59:586–95.
 - 42 Sportel BE, Nauta MH, de Hullu E, et al. Behavioral inhibition and attentional control in adolescents: robust relationships with anxiety and depression. *J Child Fam Stud* 2011;20:149–56.
 - 43 Richmond S, Kirk H, Gaunson T, et al. Digital cognitive training in children with attention-deficit/hyperactivity disorder: a study protocol of a randomised controlled trial. *BMJ Open* 2022;12:e055385.
 - 44 Hermens DF, Kohn MR, Clarke SD, et al. Sex differences in adolescent ADHD: findings from concurrent EEG and EDA. *Clin Neurophysiol* 2005;116:1455–63.
 - 45 Mahone E. Neuropsychiatric differences between boys and girls with ADHD. *Psychiatric Times* 2012;29:34–43.
 - 46 Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. *BMC Med Res Methodol* 2013;13:92.
 - 47 Jakobsen JC, Gluud C, Wetterslev J, et al. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. *BMC Med Res Methodol* 2017;17:162.
 - 48 Kao GS, Thomas HM. Test review: C. Keith Conners Conners 3rd edition Toronto, Ontario, Canada: Multi-Health systems, 2008. *J Psychoeduc Assess* 2010;28:598–602.
 - 49 Bain S, Jaspers K. Review of Kaufman brief intelligence test. *J Psychoeduc Assess* 2010;28:167–74.
 - 50 Lejuez CW, Aklon W, Daughters S, et al. Reliability and validity of the youth version of the balloon analogue risk task (BART-Y) in the assessment of risk-taking behavior among inner-city adolescents. *J Clin Child Adolesc Psychol* 2007;36:106–11.
 - 51 Macleod JW, Lawrence MA, McConnell MM, et al. Appraising the ant: psychometric and theoretical considerations of the attention network test. *Neuropsychology* 2010;24:637–51.
 - 52 Wells EL, Kofler MJ, Soto EF, et al. Assessing working memory in children with ADHD: minor administration and scoring changes may improve digit span backward's construct validity. *Res Dev Disabil* 2018;72:166–78.
 - 53 Brooks BL, Sherman EMS, Strauss E. NEPSY-II: a developmental neuropsychological assessment, second edition. *Child Neuropsychology* 2009;16:80–101.
 - 54 Hendrickson NK, McCrimmon AW. Test Review: Behavior Rating Inventory of Executive Function®, Second Edition (BRIEF®2). In: Gioia GA, Isquith PK, Guy SC, eds. Los Angeles CA, 2019: 34. 73–8.
 - 55 Mahone EM, Cirino PT, Cutting LE, et al. Validity of the behavior rating inventory of executive function in children with ADHD and/or Tourette syndrome. *Arch Clin Neuropsychol* 2002;17:643–62.
 - 56 Burton CL, Wright L, Shan J, et al. Swan scale for ADHD trait-based genetic research: a validity and polygenic risk study. *J Child Psychol Psychiatry* 2019;60:988.
 - 57 Brites C, Salgado-Azoni CA, Ferreira TL, et al. Development and applications of the Swan rating scale for assessment of attention deficit hyperactivity disorder: a literature review. *Braz J Med Biol Res* 2015;48:965.
 - 58 Cyders MA, Smith GT, Spillane NS, et al. Integration of impulsivity and positive mood to predict risky behavior: development and



- validation of a measure of positive urgency. *Psychol Assess* 2007;19:107–18.
- 59 Geurten M, Catale C, Gay P, *et al.* Measuring impulsivity in children: adaptation and validation of a short version of the UPPS-P impulsive behaviors scale in children and investigation of its links with ADHD. *Journal of Attention Disorders* 2018;1087054718775831.
- 60 Hawthorne G, Richardson J, Day NA. A comparison of the assessment of quality of life (AQoL) with four other generic utility instruments. *Ann Med* 2001;33:358–70.
- 61 Preece DA, Becerra R, Robinson K, *et al.* Measuring emotion regulation ability across negative and positive emotions: the Perth emotion regulation competency inventory (PERCI). *Pers Individ Dif* 2018;135:229–41.
- 62 Spence S. *Social Skills Training: Enhancing Social Competence with Children and Adolescents - Research and Technical Supplement*. NFER-NELSON: Berkshire, 1995.
- 63 Ramme R. Spence Children's Anxiety Scale: An Overview of Psychometric Findings, 2018. Griffith university. Available: <https://www.scaswebsite.com/docs/Ramme%20SCAS%20Psychomet%20evidence.pdf>
- 64 Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence children's anxiety scale with young adolescents. *J Anxiety Disord* 2003;17:605–25.
- 65 Biederman J, Monuteaux MC, Kendrick E, *et al.* The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD. *Arch Dis Child* 2005;90:1010.
- 66 Ebesutani C, Bernstein A, Nakamura BJ, *et al.* Concurrent validity of the child behavior checklist DSM-Oriented scales: correspondence with DSM diagnoses and comparison to syndrome scales. *J Psychopathol Behav Assess* 2010;32:373.
- 67 Bruni TP. *Test review: social responsiveness Scale—Second edition (SRS-2)*. Los Angeles, CA, 2014: 32. 365–9.
- 68 Bihun JT, Wamboldt MZ, Gavin LA, *et al.* Can the family assessment device (FAD) be used with school aged children? *Fam Process* 2002;41:723–31.
- 69 Fristad MA. A comparison of the McMaster and CIRCUMPLEX family assessment INSTRUMENTS*. *J Marital Fam Ther* 1989;15:259–69.